In the Zone

$STEM - Stem Cells, Inc.

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for academia and industry. It develops cell-based therapeutics for the central nervous system and liver.

The companys product candidate HuCNS-SC cells has completed a Phase I clinical trial for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis, a neurodegenerative disorder of the brain; and completed a Phase I clinical trial for the treatment of Pelizeaus-Merzbacher disease, a fatal myelination disorder in the brain. It also engages in developing HuCNS-SC cells, which are in Phase I/II clinical trial for the treatment of chronic spinal cord injury; and HuCNS-SC cells that are in Phase I/II clinical trial for the treatment of dry age-related macular degeneration.

In addition, the company identifies and develops human liver engrafting cells for a range of liver diseases; and is involved in developing and commercializing applications of its technologies to enable stem cell-based research.

Further, it markets a range of proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2B27, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents under the SC Proven brand comprising STEM24, STEM101, STEM121, and STEM123 for cell detection, isolation, and characterization.

The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

Please keep (STEM) Stem Cells, Inc. on your radar for an increase in price above $1.80 - $1.85 on heavier than average daily trading volume of 1.74 million..

As of the closing of trading on Friday (STEM) Stem Cells, Inc. closed to end the week trading at  ended the week trading at $9.08 +0.26 or +3.32% on lighter than average upside trading volume of 964,485.

The average weekly trading volume for (STEM) Stem Cells, Inc. is 1.74 million. Please note that this is not a buy recommendation please do your own due diligence or get help from a professional before trading.

By: Marlin Rolle
*** Please have a close look at the charts listed below ****